EUVIMEDEUVIMED entdecken
Crossref

The impact of change in regulations on buprenorphine prescribing for opioid use disorder

Evon Ibrahim, Kaitlyn DeHoff, Eric Lambart, Molly Bray, Mary Marogi

American Journal of Health-System Pharmacy · 2025

DOI: 10.1093/ajhp/zxaf035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Health-System Pharmacy, 2025. Verfasst von Evon Ibrahim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Trinity Health Oakland Hospital, Pontiac, MI, USA. Hauptthemen laut MEDLINE: Buprenorphine, Opioid-Related Disorders, Opiate Substitution Treatment, Narcotic Antagonists. Die Arbeit nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

In December 2022, federal regulations in the US changed to increase access to buprenorphine for patients who need treatment for opioid use disorder (OUD), removing the requirement for prescribers to obtain a DATA waiver. This study’s purpose was to evaluate the impact of these changes in regulations on buprenorphine prescribing for OUD at a community teaching hospital.

Methods

This single-center, retrospective cohort study investigated buprenorphine prescribing habits before and after the requirement for a DATA waiver was removed. The study focused on patients who had a diagnosis code for OUD or had buprenorphine with or without naloxone ordered for OUD from March 1 to December 20, 2022 (before the changes) and from March 1 to December 20, 2023 (after the changes). The primary outcome was the percentage of patients with OUD who received buprenorphine with or without naloxone before and after the changes in regulations.

Results

Of the 386 patients for whom charts were reviewed, 162 patients met the inclusion criteria: 81 patients in the before group and 81 patients in the after group. Before the changes in regulations, 40% of patients with OUD had buprenorphine ordered in the inpatient setting, compared to 63% of patients after regulations were changed (P = 0.003). More patients had their home buprenorphine regimen continued in the inpatient setting in the after group than in the before group (53% vs 37%; P = 0.04).

Conclusion

After removal of the DATA waiver requirement for buprenorphine prescribing, more patients with OUD were prescribed buprenorphine during hospitalization and at discharge.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuprenorphineOpioid-Related DisordersOpiate Substitution TreatmentNarcotic AntagonistsPractice Patterns, Physicians'HumansRetrospective StudiesMaleFemaleMiddle AgedAdultNaloxoneCohort StudiesAnalgesics, OpioidDrug Prescriptions

Stichwörter der Autor:innen

DATA waiverX waiverbuprenorphinefederal regulationsopioid use disorderopioid withdrawal

Substanzen

BuprenorphineNarcotic AntagonistsNaloxoneAnalgesics, Opioid

Autor:innen und Institutionen

  • Trinity Health Oakland Hospital, Pontiac, MI, USA.

Zitieren

APA

Ibrahim, E., DeHoff, K., Lambart, E., Bray, M., & Marogi, M. (2025). The impact of change in regulations on buprenorphine prescribing for opioid use disorder. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxaf035

Vancouver

Ibrahim E, DeHoff K, Lambart E, Bray M, Marogi M. The impact of change in regulations on buprenorphine prescribing for opioid use disorder. American Journal of Health-System Pharmacy. 2025. doi:10.1093/ajhp/zxaf035

BibTeX
@article{Ibrahim2025,
  author = {Ibrahim, Evon and DeHoff, Kaitlyn and Lambart, Eric and Bray, Molly and Marogi, Mary},
  title = {The impact of change in regulations on buprenorphine prescribing for opioid use disorder},
  journal = {American Journal of Health-System Pharmacy},
  year = {2025},
  doi = {10.1093/ajhp/zxaf035}
}
Kostenlos starten →